Pulmatrix Company Leadership
PULM Stock | USD 2.02 0.03 1.51% |
About 66 percent of all Pulmatrix's insiders are acquiring. The analysis of insiders' sentiment of trading Pulmatrix stock suggests that many insiders are confidant at this time. Pulmatrix employs about 22 people. The company is managed by 24 executives with a total tenure of roughly 154 years, averaging almost 6.0 years of service per executive, having 0.92 employees per reported executive.
Robert Clarke CEO CEO and President and Director |
Ted Raad CEO CEO, Director |
Pulmatrix's Insider Buying Vs Selling
66
Selling | Buying |
Latest Trades
2015-06-16 | Steven Gillis | Acquired 72750 @ 6.88 | View | ||
2015-06-15 | Terrance Mcguire | Acquired 106693 @ 6.88 | View | ||
2015-03-23 | Innovative Sciences In Oculus | Disposed 350000 @ 2.75 | View |
Monitoring Pulmatrix's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Pulmatrix |
Pulmatrix's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Pulmatrix's future performance. Based on our forecasts, it is anticipated that Pulmatrix will maintain a workforce of about 20 employees by May 2024.Pulmatrix Management Team Effectiveness
The company has return on total asset (ROA) of (0.246) % which means that it has lost $0.246 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5752) %, meaning that it created substantial loss on money invested by shareholders. Pulmatrix's management efficiency ratios could be used to measure how well Pulmatrix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.52. At this time, Pulmatrix's Total Current Assets are very stable compared to the past year. As of the 24th of April 2024, Net Tangible Assets is likely to grow to about 37.6 M, while Non Current Assets Total are likely to drop about 8.2 M.As of the 24th of April 2024, Common Stock Shares Outstanding is likely to grow to about 3.8 M, while Net Loss is likely to drop (17.8 M).
Pulmatrix Workforce Comparison
Pulmatrix is rated below average in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 982. Pulmatrix holds roughly 22.0 in number of employees claiming about 2.24% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.93) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.01) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.01. Pulmatrix Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulmatrix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulmatrix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pulmatrix insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2020-09-01 | 1.0 | 8 | 8 | 55,602 | 55,602 |
2019-06-01 | 4.0 | 8 | 2 | 570,000 | 1,247 |
2017-03-01 | 5.0 | 10 | 2 | 337,988 | 6,788 |
2015-12-01 | 1.0 | 2 | 2 | 92,299 | 760.00 |
2015-06-01 | 40.5 | 81 | 2 | 15,052,238 | 1,650,000 |
Pulmatrix Notable Stakeholders
A Pulmatrix stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pulmatrix often face trade-offs trying to please all of them. Pulmatrix's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pulmatrix's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert Clarke | CEO and President and Director | Profile | |
Ted Raad | CEO, Director | Profile | |
Teofilo MBA | CEO President | Profile | |
Teofilo Raad | CEO, Director | Profile | |
Mark Iwicki | Chairman of the Board | Profile | |
Jean Sung | Vice President - Pharmaceutical Development | Profile | |
William Duke | CFO, Principal Financial Officer & Principal Accounting Officer | Profile | |
Terrance McGuire | Director | Profile | |
Matthew Sherman | Director | Profile | |
Akihisa Akao | Director | Profile | |
Michael Higgins | Director | Profile | |
Steven Gillis | Director | Profile | |
Scott Rocklage | Director | Profile | |
Kurt Graves | Director | Profile | |
Richard Conley | Independent Director | Profile | |
Amit Munshi | Director | Profile | |
Gregory French | Independent Director | Profile | |
MBA CMA | Interim Officer | Profile | |
David Hava | Chief Scientific Officer | Profile | |
Alexander Klibanov | Founder | Profile | |
James Roach | Chief Medical Officer | Profile | |
Margaret MD | Chief Officer | Profile | |
David JD | Advisor | Profile | |
Aidan Curran | VP Affairs | Profile |
About Pulmatrix Management Performance
The success or failure of an entity such as Pulmatrix often depends on how effective the management is. Pulmatrix management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pulmatrix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pulmatrix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.42) | (0.44) | |
Return On Capital Employed | (0.49) | (0.52) | |
Return On Assets | (0.42) | (0.44) | |
Return On Equity | (0.78) | (0.82) |
The data published in Pulmatrix's official financial statements usually reflect Pulmatrix's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Pulmatrix. For example, before you start analyzing numbers published by Pulmatrix accountants, it's critical to develop an understanding of what Pulmatrix's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Pulmatrix's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pulmatrix's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Pulmatrix's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pulmatrix. Please utilize our Beneish M Score to check the likelihood of Pulmatrix's management manipulating its earnings.
Pulmatrix Workforce Analysis
Traditionally, organizations such as Pulmatrix use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pulmatrix within its industry.Pulmatrix Manpower Efficiency
Return on Pulmatrix Manpower
Revenue Per Employee | 331.7K | |
Revenue Per Executive | 304.1K | |
Net Loss Per Employee | 641.9K | |
Net Loss Per Executive | 588.4K | |
Working Capital Per Employee | 769.7K | |
Working Capital Per Executive | 705.6K |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Pulmatrix Stock analysis
When running Pulmatrix's price analysis, check to measure Pulmatrix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulmatrix is operating at the current time. Most of Pulmatrix's value examination focuses on studying past and present price action to predict the probability of Pulmatrix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulmatrix's price. Additionally, you may evaluate how the addition of Pulmatrix to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Pulmatrix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.87) | Revenue Per Share 1.998 | Quarterly Revenue Growth 0.289 | Return On Assets (0.25) | Return On Equity (0.58) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.